Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
Status:
Withdrawn
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-site, randomized, prospective, open-label phase II study. Patients in this
study will have localized (cT3-cT4), or metastatic bladder cancer with a symptomatic, intact
primary bladder tumor. In this study, patients will undergo stereotactic body radiation
therapy (SBRT) to the bladder tumor and will receive durvalumab with or without tremelimumab.